Biotech Fund Sells Erasca Stake After 700% Rally
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: Yahoo Finance
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 18.850
Low
2.00
Averages
5.50
High
11.00
Current: 18.850
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following patent infringement allegations from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating a severe erosion of investor confidence in its ERAS-0015 product.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, alleging that the company misled investors between January 14, 2025, and April 26, 2026, potentially exposing investors to significant losses and highlighting the company's legal compliance risks.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's RMC-6236 and failing to disclose challenges to the validity of its intellectual property, which could undermine its competitive position in the market.
- Patient Safety Incident: Following treatment with ERAS-0015, a patient experienced an adverse event and subsequently died, further intensifying market concerns regarding the safety profile of Erasca's product and potentially prompting regulatory scrutiny.
See More
Erasca Inc. Class Action Lawsuit Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: Erasca, along with its CEO and CFO, is accused of violating federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, during the class period, resulting in investor losses.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its success and resource advantages in this field.
- Investor Action Recommendation: Investors can visit Rosen Law Firm's website or call the toll-free number for more information and choose qualified legal counsel to ensure their rights are effectively protected.
See More
Erasca Shareholder Files Securities Class Action Lawsuit
- Class Action Initiated: A shareholder has filed a securities class action lawsuit on behalf of investors who purchased Erasca, Inc. common stock between January 14, 2025, and April 26, 2026, alleging that the company made materially false and misleading statements that inflated stock prices during this period.
- Claims for Damages: The lawsuit claims that due to the defendants' misrepresentations, Erasca's common stock traded at artificially inflated prices, resulting in significant losses for investors when the truth was revealed, prompting demands for compensation for affected shareholders.
- Participation Guidance: Investors are encouraged to act promptly and submit a form to participate in the lawsuit; those wishing to serve as lead plaintiff must file by August 10, 2026, with all representation on a contingency fee basis, meaning shareholders incur no fees.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its success in litigating class actions, highlighting its strong reputation in the securities litigation field.
See More
Erasca Shareholder Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiff by August 10, 2026, to represent other shareholders in the class action lawsuit.
- Lawsuit Background: The lawsuit alleges that Erasca and its CEO and CFO violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, resulting in investor losses when the truth was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record in this field.
- Participation Instructions: Investors can join the class action by visiting the Rosen Law Firm website or calling the toll-free number for more information, with no upfront fees required, ensuring the protection of investor rights.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations from Revolution Medicines of patent infringement, resulting in a loss of over $2.8 billion in market capitalization, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, alleging violations of federal securities laws, which could lead to further investor losses.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's RMC-6236 without disclosing potential intellectual property disputes, which may undermine investor confidence in its product offerings.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015, the market reacted sharply, exacerbating concerns over the product's safety and potentially impacting future clinical trials and market rollout.
See More
Erasca Faces Class Action Lawsuit Risk
- Lawsuit Background: Erasca, Inc. is facing a class action lawsuit due to allegations of patent infringement against Revolution Medicines, impacting investors who purchased stock between January 14, 2025, and April 26, 2026, highlighting significant legal risks in the company's drug development.
- Stock Price Plunge: On April 27, 2026, Erasca's stock price fell by $2.34, or 10.9%, closing at $19.15 after receiving a legal letter, indicating strong market reactions to the company's legal troubles.
- Clinical Data Disclosure: The same day, Erasca reported preliminary clinical data for ERAS-0015, revealing a patient death one month after starting treatment, causing the stock to plummet further by $9.25, or 48.3%, to $9.90 on April 28, severely harming investor interests.
- False Statement Allegations: The class action lawsuit alleges that throughout the class period, Erasca failed to disclose significant adverse facts regarding ERAS-0015, misleading investors about the company's prospects and reflecting a critical lack of transparency in corporate communications.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following patent infringement allegations from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating a severe erosion of investor confidence in its ERAS-0015 product.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, alleging that the company misled investors between January 14, 2025, and April 26, 2026, potentially exposing investors to significant losses and highlighting the company's legal compliance risks.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's RMC-6236 and failing to disclose challenges to the validity of its intellectual property, which could undermine its competitive position in the market.
- Patient Safety Incident: Following treatment with ERAS-0015, a patient experienced an adverse event and subsequently died, further intensifying market concerns regarding the safety profile of Erasca's product and potentially prompting regulatory scrutiny.
See More
Erasca Inc. Class Action Lawsuit Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: Erasca, along with its CEO and CFO, is accused of violating federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, during the class period, resulting in investor losses.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its success and resource advantages in this field.
- Investor Action Recommendation: Investors can visit Rosen Law Firm's website or call the toll-free number for more information and choose qualified legal counsel to ensure their rights are effectively protected.
See More
Erasca Shareholder Files Securities Class Action Lawsuit
- Class Action Initiated: A shareholder has filed a securities class action lawsuit on behalf of investors who purchased Erasca, Inc. common stock between January 14, 2025, and April 26, 2026, alleging that the company made materially false and misleading statements that inflated stock prices during this period.
- Claims for Damages: The lawsuit claims that due to the defendants' misrepresentations, Erasca's common stock traded at artificially inflated prices, resulting in significant losses for investors when the truth was revealed, prompting demands for compensation for affected shareholders.
- Participation Guidance: Investors are encouraged to act promptly and submit a form to participate in the lawsuit; those wishing to serve as lead plaintiff must file by August 10, 2026, with all representation on a contingency fee basis, meaning shareholders incur no fees.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its success in litigating class actions, highlighting its strong reputation in the securities litigation field.
See More
Erasca Shareholder Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiff by August 10, 2026, to represent other shareholders in the class action lawsuit.
- Lawsuit Background: The lawsuit alleges that Erasca and its CEO and CFO violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, resulting in investor losses when the truth was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record in this field.
- Participation Instructions: Investors can join the class action by visiting the Rosen Law Firm website or calling the toll-free number for more information, with no upfront fees required, ensuring the protection of investor rights.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations from Revolution Medicines of patent infringement, resulting in a loss of over $2.8 billion in market capitalization, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, alleging violations of federal securities laws, which could lead to further investor losses.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's RMC-6236 without disclosing potential intellectual property disputes, which may undermine investor confidence in its product offerings.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015, the market reacted sharply, exacerbating concerns over the product's safety and potentially impacting future clinical trials and market rollout.
See More
Erasca Faces Class Action Lawsuit Risk
- Lawsuit Background: Erasca, Inc. is facing a class action lawsuit due to allegations of patent infringement against Revolution Medicines, impacting investors who purchased stock between January 14, 2025, and April 26, 2026, highlighting significant legal risks in the company's drug development.
- Stock Price Plunge: On April 27, 2026, Erasca's stock price fell by $2.34, or 10.9%, closing at $19.15 after receiving a legal letter, indicating strong market reactions to the company's legal troubles.
- Clinical Data Disclosure: The same day, Erasca reported preliminary clinical data for ERAS-0015, revealing a patient death one month after starting treatment, causing the stock to plummet further by $9.25, or 48.3%, to $9.90 on April 28, severely harming investor interests.
- False Statement Allegations: The class action lawsuit alleges that throughout the class period, Erasca failed to disclose significant adverse facts regarding ERAS-0015, misleading investors about the company's prospects and reflecting a critical lack of transparency in corporate communications.
See More
